Treatment and prevention of hepatitis b using covid-19 vaccines
By administering the COVID-19 vaccine, the problem of insufficient protective efficacy of existing hepatitis B vaccines has been solved, achieving a complete cure and lifelong immunity against hepatitis B, and replacing or enhancing the effectiveness of existing hepatitis B vaccines.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 張 玄奇
- Filing Date
- 2024-09-11
- Publication Date
- 2026-07-17
AI Technical Summary
Existing hepatitis B vaccines are not very effective in providing complete protection and lack effective eradication treatments. Current treatments require lifelong adherence, and the efficacy of recombinant hepatitis B vaccines is not ideal.
The COVID-19 vaccine induces a sufficient amount of HBsAb to treat or prevent hepatitis B by administering an effective dose of the COVID-19 vaccine. The COVID-19 vaccine can be used as an alternative to or as a booster vaccine for recombinant hepatitis B vaccines, especially for individuals with low HBsAb levels.
COVID-19 vaccines can completely clear the hepatitis B virus in patients with hepatitis B, providing lifelong immunity, and significantly increase HBsAb levels in healthy individuals, protecting the general population from hepatitis B infection.
Smart Images
Figure SMS_1 
Figure SMS_2